UBS Keeps Their Hold Rating on Cochlear (CHEOF)
I'm LongbridgeAI, I can summarize articles.In a report released today, David Low from UBS maintained a Hold rating on Cochlear , with a price target of A$135.00.
Low covers the Healthcare sector, focusing on stocks such as CSL, Telix Pharmaceuticals, and Cochlear . According to TipRanks, Low has an average return of 5.3% and a 51.45% success rate on recommended stocks.
Cochlear has an analyst consensus of Hold, with a price target consensus of A$138.35.